Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shore

Showing results (441-450 of 590) with videos related to

Pageof 59
Sort By:
BJU International|July 31, 2025
Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamideNicole Handa, Neal D Shore, Matthew R Cooperberg, et al.
The Journal of Urology|September 26, 2015
Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate CancerNeal D Shore, Naveen Kella, Brian Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE TrialsEmmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, et al.
Journal of the American College of Surgeons|July 31, 2010
Reduced incidence of gestational diabetes with bariatric surgeryAnne E Burke, Wendy L Bennett, Roxanne M Jamshidi, et al.
Clinical Genitourinary Cancer|July 31, 2025
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II StudyNeal D Shore, K Kent Chevli, Daniel Saltzstein, et al.
The Journal of Urology|May 13, 2026
Semen RNA-Based Biomarkers for Prostate Cancer Detection and Risk Stratification: A Prospective Multi-Center Validation StudyDuncan H Whitney, Matthew Clay, Joel Wipperfurth, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2024
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancerUlka N Vaishampayan, Marianne Keessen, Robert Dreicer, et al.
Future Oncology (London, England)|February 9, 2018
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPETScott C Flanders, Janet Kim, Samuel Wilson, et al.
European Urology Focus|December 19, 2025
Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and ChallengesNeal D Shore, Stephen J Freedland, Lisa G Horvath, et al.
Future Oncology (London, England)|June 2, 2025
rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPCKim Nguyen Chi, Rana R McKay, Shahneen Sandhu, et al.
Pageof 59

Showing results (441-450 of 590) with videos related to

Sort By:
Pageof 59
BJU International|July 31, 2025
Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamideNicole Handa, Neal D Shore, Matthew R Cooperberg, et al.
The Journal of Urology|September 26, 2015
Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate CancerNeal D Shore, Naveen Kella, Brian Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE TrialsEmmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, et al.
Journal of the American College of Surgeons|July 31, 2010
Reduced incidence of gestational diabetes with bariatric surgeryAnne E Burke, Wendy L Bennett, Roxanne M Jamshidi, et al.
Clinical Genitourinary Cancer|July 31, 2025
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II StudyNeal D Shore, K Kent Chevli, Daniel Saltzstein, et al.
The Journal of Urology|May 13, 2026
Semen RNA-Based Biomarkers for Prostate Cancer Detection and Risk Stratification: A Prospective Multi-Center Validation StudyDuncan H Whitney, Matthew Clay, Joel Wipperfurth, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2024
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancerUlka N Vaishampayan, Marianne Keessen, Robert Dreicer, et al.
Future Oncology (London, England)|February 9, 2018
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPETScott C Flanders, Janet Kim, Samuel Wilson, et al.
European Urology Focus|December 19, 2025
Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and ChallengesNeal D Shore, Stephen J Freedland, Lisa G Horvath, et al.
Future Oncology (London, England)|June 2, 2025
rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPCKim Nguyen Chi, Rana R McKay, Shahneen Sandhu, et al.
Pageof 59